IP Waiver Proposal Won’t Hold Back Moderna’s Rise
Bancel: 'IP Is Not The Issue'
While White House support for an intellectual property waiver has been cheered by access campaigners, Moderna said it won’t help solve the pandemic’s big vaccine production challenges any time soon.
You may also be interested in...
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.